Darakhshan Sara, Bidmeshkipour Ali, Khazaei Mozafar, Rabzia Arezou, Ghanbari Ali
Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran E-mail :
Asian Pac J Cancer Prev. 2013;14(11):6869-74. doi: 10.7314/apjcp.2013.14.11.6869.
Vascular endothelial growth factor and matrix metalloproteinases are two important factors for angiogenesis associated with breast cancer growth and progression. The present study was aimed to examine the effects of tamoxifen and tranilast drugs singly or in combination on proliferation of breast cancer cells and also to evaluate VEGF and MMP-9 expression and VEGF secretion levels.
Human breast cancer cell lines, MCF-7 and MDA-MB-231, were treated with tamoxifen and/or tranilast alone or in combination and percentage cell survival and proliferative activity were evaluated using LDH leakage and MTT assays. mRNA expression and protein levels were examined by real-time RT-PCR and ELISA assay, respectively.
LDH and MTT assays showed that the combined treatment of tamoxifen and tranilast resulted in a significant decrease in cell viability and cell proliferation compared with tamoxifen or tranilast treatment alone, with significant decrease in VEGF mRNA and protein levels. We also found that tamoxifen as a single agent rarely increased MMP-9 expression. A decrease in MMP-9 expression was seen after treatment with tranilast alone and in the combined treatment MMP-9 mRNA level was decreased.
This combination treatment can able to inhibit growth, proliferation and angiogenesis of breast cancer cells.
血管内皮生长因子和基质金属蛋白酶是与乳腺癌生长和进展相关的血管生成的两个重要因素。本研究旨在研究他莫昔芬和曲尼司特单独或联合用药对乳腺癌细胞增殖的影响,并评估血管内皮生长因子(VEGF)和基质金属蛋白酶-9(MMP-9)的表达及VEGF分泌水平。
用人乳腺癌细胞系MCF-7和MDA-MB-231分别单独或联合使用他莫昔芬和/或曲尼司特进行处理,采用乳酸脱氢酶(LDH)释放法和MTT法评估细胞存活率和增殖活性。分别通过实时逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附测定(ELISA)检测mRNA表达和蛋白水平。
LDH和MTT分析表明与单独使用他莫昔芬或曲尼司特相比,他莫昔芬和曲尼司特联合处理导致细胞活力和细胞增殖显著降低,VEGF mRNA和蛋白水平也显著下降。我们还发现他莫昔芬作为单一药物很少增加MMP-9表达。单独使用曲尼司特处理后MMP-9表达下降,联合处理后MMP-9 mRNA水平降低。
这种联合治疗能够抑制乳腺癌细胞的生长、增殖和血管生成。